Teva Pharmaceutical sees more growth in 2025 after strong Q3
Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...
FiercePharma10d
Teva's generics and biosimilars fuel another booming quarter
As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...
Teva Pharmaceutical Industries (TEVA) Scheduled to Post Quarterly Earnings on Wednesday
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...
Market Whales and Their Recent Bets on TEVA Options
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Call Transcript
EPS, expectations were $0.66. Operator: Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings ...
ETF Daily News8d
Zacks Research Issues Optimistic Estimate for TEVA Earnings
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty ...
The Associated Press on MSN16d
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) ...
Seeking Alpha16d
Teva fined $500M by EU for disparaging rival MS drug (update)
“Teva (TEVA) conducts its business lawfully and ethically and has been a strong partner to Europe, its patients, economy and healthcare systems,” the company added.